3rd Gamma Delta T Therapies Summit 2022

With Adicet Bio, In8Bio, Gamma Delta Therapeutics, Lava Therapeutics, and ImCheck Therapeutics releasing clinical data from engineered and antibody-based γδT Therapy in patients; the race to market for the first allogeneic and solid tumor-targeting γδT Therapy is truly on.

Join the 3rd Gamma Delta T Therapies Summit to learn and network with 120+ of the world's leaders including γδT pioneer, Adrian Hayday, and together accelerate the development of effective, persistent, globally accessible cell therapy for solid tumors.

Enhance cytotoxicity, discover novel targets, engineer stealth and persistence, interrogate cell subsets, and scale-up manufacturing through a deep understanding of the fundamental biology and target product profile for γδT therapies.

Industry experts agree that this year, the γδT is the cell to know. Ensure you and your team are ahead of the curve and equipped with the need-to-know insights to advance successful therapeutics, across 2 dedicated tracks covering Discovery, Process Research, Preclinical, and Clinical Development; as well as 3 deep-dive workshops, and a Gamma Delta 101 Bootcamp.

 

Speakers: Blake Aftab, CSO, Adicet Bio, Francesco Galimi, CMO, Adicet Bio, Sai-Wen Tang, Director, R and D Acepodia, Frank Borriello, Scientific Founder and CEO, Alloplex Biotherapeutics, Jim Lederer, Associate Professor, Brigham and Women's Hospital, Mark Wallet, VP Head of Immunology, Century Therapeutics, Cheng Liu, President and CEO, Eureka Therapeutics, Stefania Gobessi, Director of Discovery, Gadeta, Oliver Nussbaumer, VP Immunology, GammaDelta Therapeutics, Victoria Coutinho, VP Regulatory Affairs, GammaDelta Therapeutics, Jonathan Fisher, Wellcome Trust Clinical Research Fellow, Great Ormand Street Hospital, UCL, Marta Barisa, Senior Research Fellow and Scientific Project Manager, Great Ormond Street Hospital, UCL, Paul Frohna, CMO, ImCheck Therapeutics, Annelise Vuidepot, CTO and Head of Platform and Pipeline Development, Immunocore, Kate Rochlin, COO, In8Bio, Lawrence Lamb, EVP, CSO and Co- Founder, IN8Bio, Daniel Olive, Group Leader, INSERM, Bruno Silva-Santos, Group Leader, Instituto de Medicina Molecular, Paul Parren, Head of R and D, Lava Therapeutics, Rob Roovers, Senior Director Preclinical Development, Lava Therapeutics, Caroline Hull, Team Lead, Leucid Bio, Daniel Abate-Daga, Associate Member, Moffitt Cancer Center, Richard Lopez, Founder and CEO, PhosphoGam, Jianqiang Li, Founder and CSO, SenlangBio, Serhat Gumrukcu, Executive Director and Director of Translational Research, Seraph Research Institute, Anne Lai, Principal Scientist, Shattuck Labs, Alice Cheung, Senior Research Scientist, Singapore General Hospital, Alice Bertaina, Associate Professor of Pediatrics, Stanford, Angela Scott, Co-Founder and COO, TC Biopharm, Emilio Cosimo, Product Development Manager, TC Biopharm, Michael Leek, Co-Founder and Executive Chairman, TC Biopharm, Adrian Hayday, Senior Group Leader, The Francis Crick Institute, John Anderson, Professor of Experimental Pediatric Oncology and Honorary Consultant Oncologist, UCL Great Ormond Street Institute of Child Health

Others Details

Brochure: https://go.evvnt.com/1089722-0?pid=6581